101 related articles for article (PubMed ID: 27664008)
1. Dietary flavonoid derivatives enhance chemotherapeutic effect by inhibiting the DNA damage response pathway.
Kuo CY; Zupkó I; Chang FR; Hunyadi A; Wu CC; Weng TS; Wang HC
Toxicol Appl Pharmacol; 2016 Nov; 311():99-105. PubMed ID: 27664008
[TBL] [Abstract][Full Text] [Related]
2. ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
Li CC; Yang JC; Lu MC; Lee CL; Peng CY; Hsu WY; Dai YH; Chang FR; Zhang DY; Wu WJ; Wu YC
Oncotarget; 2016 Jan; 7(2):1947-59. PubMed ID: 26657501
[TBL] [Abstract][Full Text] [Related]
3. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
4. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
5. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1.
Zhao H; Piwnica-Worms H
Mol Cell Biol; 2001 Jul; 21(13):4129-39. PubMed ID: 11390642
[TBL] [Abstract][Full Text] [Related]
6. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
7. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
Thompson R; Meuth M; Woll P; Zhu Y; Danson S
Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
[TBL] [Abstract][Full Text] [Related]
8. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA polymerase eta-deficient human cells treated with cisplatin and oxaliplatin.
Cruet-Hennequart S; Glynn MT; Murillo LS; Coyne S; Carty MP
DNA Repair (Amst); 2008 Apr; 7(4):582-96. PubMed ID: 18289945
[TBL] [Abstract][Full Text] [Related]
9. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells.
Peralta-Sastre A; Manguan-Garcia C; de Luis A; Belda-Iniesta C; Moreno S; Perona R; Sanchez-Perez I
Int J Biochem Cell Biol; 2010 Feb; 42(2):318-28. PubMed ID: 19931410
[TBL] [Abstract][Full Text] [Related]
11. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
12. Wortmannin potentiates the combined effect of etoposide and cisplatin in human glioma cells.
Pastwa E; Poplawski T; Lewandowska U; Somiari SB; Blasiak J; Somiari RI
Int J Biochem Cell Biol; 2014 Aug; 53():423-31. PubMed ID: 24953561
[TBL] [Abstract][Full Text] [Related]
13. Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells.
Cho JH; Lee JG; Yang YI; Kim JH; Ahn JH; Baek NI; Lee KT; Choi JH
Food Chem Toxicol; 2011 Aug; 49(8):1737-44. PubMed ID: 21554918
[TBL] [Abstract][Full Text] [Related]
14. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
15. Dietary flavonoids and cancer risk in the Zutphen Elderly Study.
Hertog MG; Feskens EJ; Hollman PC; Katan MB; Kromhout D
Nutr Cancer; 1994; 22(2):175-84. PubMed ID: 14502846
[TBL] [Abstract][Full Text] [Related]
16. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Agner J; Falck J; Lukas J; Bartek J
Exp Cell Res; 2005 Jan; 302(2):162-9. PubMed ID: 15561098
[TBL] [Abstract][Full Text] [Related]
17. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
18. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide.
Rünger TM; Emmert S; Schadendorf D; Diem C; Epe B; Hellfritsch D
J Invest Dermatol; 2000 Jan; 114(1):34-9. PubMed ID: 10620112
[TBL] [Abstract][Full Text] [Related]
19. DNA damage response (DDR) pathway engagement in cisplatin radiosensitization of non-small cell lung cancer.
Sears CR; Cooney SA; Chin-Sinex H; Mendonca MS; Turchi JJ
DNA Repair (Amst); 2016 Apr; 40():35-46. PubMed ID: 26991853
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
Teng PN; Bateman NW; Darcy KM; Hamilton CA; Maxwell GL; Bakkenist CJ; Conrads TP
Gynecol Oncol; 2015 Mar; 136(3):554-61. PubMed ID: 25560806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
